CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
CP-690,550 Ointment 1 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01246583
NCT01246583Phase 2Completed

A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS

Pfizer·interventional·Posted Nov 23, 2010·Updated Jan 11, 2021

In Brief

A Phase 2 clinical trial evaluating CP-690,550 Ointment 1, Vehicle 1, and 2 other interventions for Psoriasis. Completed, enrolled 71 participants across 12 sites in 2 countries.

Detailed Summary

The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 23, 2010
Enrollment StartFeb 16, 2011
Primary CompletionNov 29, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.6 years ago

Interventions

CP-690,550 Ointment 1drug

2% CP-690,550 Ointment 1 twice daily for 4 weeks

Vehicle 1drug

Vehicle 1 twice daily for 4 weeks

CP-690,550 Ointment 2drug

2% CP-690,550 Ointment 2 twice daily for 4 weeks

Vehicle 2drug

Vehicle 2 twice daily for 4 weeks